Lip and oral cavity squamous cell carcinoma
diseaseOn this page
Also known as lip and oral cavity squamous cell cancerlip/oral cavity squam. cell car.
Summary
Lip and oral cavity squamous cell carcinoma (MONDO:0044710) is a cancer and 13 clinical trials. Top therapeutic interventions include cisplatin, atezolizumab, and cetuximab. A subtype of head and neck squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 13
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | lip and oral cavity squamous cell carcinoma |
| Mondo ID | MONDO:0044710 |
| Orphanet | 502369 |
| NCIT | C42690 |
| UMLS | C0280297 |
| MedGen | 124714 |
| GARD | 0022046 |
| Is cancer (heuristic) | yes |
Also known as: lip and oral cavity squamous cell cancer · lip and oral cavity squamous cell carcinoma · lip/oral cavity squam. cell car.
Disease family
This is a subtype of head and neck squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › head and neck carcinoma › head and neck squamous cell carcinoma › lip and oral cavity squamous cell carcinoma
Related subtypes (12): pharyngeal squamous cell carcinoma, cornea squamous cell carcinoma, lacrimal gland squamous cell carcinoma, external ear squamous cell carcinoma, laryngeal squamous cell carcinoma, nasal cavity squamous cell carcinoma, nasopharyngeal squamous cell carcinoma, conjunctival squamous cell carcinoma, middle ear squamous cell carcinoma, primary intraosseous squamous cell carcinoma, paranasal sinus squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma
Subtypes (1): oral cavity squamous cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 13.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 8 |
| Not specified | 2 |
| PHASE3 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00588770 | PHASE3 | ACTIVE_NOT_RECRUITING | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| NCT05063552 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers |
| NCT02734537 | PHASE2 | RECRUITING | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery |
| NCT00458978 | PHASE2 | COMPLETED | Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer |
| NCT01256385 | PHASE2 | COMPLETED | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy |
| NCT01414426 | PHASE2 | COMPLETED | Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions |
| NCT02007200 | PHASE2 | COMPLETED | Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery |
| NCT02068157 | PHASE2 | TERMINATED | Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer |
| NCT02196168 | PHASE2 | TERMINATED | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT03422536 | PHASE2 | COMPLETED | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma |
| NCT01254617 | PHASE1 | COMPLETED | Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer |
| NCT01816841 | Not specified | COMPLETED | Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care |
| NCT03032250 | Not specified | COMPLETED | Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 4 |
| ATEZOLIZUMAB | 4 | 1 |
| CETUXIMAB | 4 | 1 |
| PORFIMER SODIUM | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| VANDETANIB | 4 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| FICLATUZUMAB | 3 | 1 |
| SOY ISOFLAVONES | 2 | 1 |
| CHEMBL5412235 | 0 | 1 |
Related Atlas pages
- Drugs: Cisplatin, Atezolizumab, Cetuximab, Porfimer, Temsirolimus, Vandetanib, Cediranib, Ficlatuzumab